This article was originally published in The Gray Sheet
Stryker CFO retires and Osiris Therapeutics CEO resigns, as SpineGuard and Tandem Diabetes Care expand management teams.
You may also be interested in...
Tandem Diabetes Adds Special Touch (Screen) To Integrated Pump-Monitor Space
Tandem Diabetes Care’s t:slim G4 insulin pump/continuous glucose monitor system is the latest DexCom partnership to yield an FDA approval, and the first integrated diabetes system to feature a touch-screen display.
US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month
Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.
Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings
More formal meetings are available for in-person sessions with the US FDA. Also, CBER Director Peter Marks offers advice for conducting meetings, from how to do hybrid right to how to include patient groups and foreign regulators.